CONTACT US Eric Smith Lab for Synthetic Biology and Cellular Enginnering
The Eric Smith Lab for Synthetic Biology and Cellular Engineering is always on the look out for exceptional scientists and opportunities for collaboration. Please contact Dr. Smith at: EricL_Smith[at]dfci.harvard.edu directly for these inquires.
We are actively recruiting highly motivated, forward thinking, and innovative postdoctoral research fellows, PhD students and scientists. Trainees will gain experience at every step of the translational research process; from using the latest advances in transgene design/genetic engineering (lentiviral and/or CRISPR based) and cellular manipulation, through in vitro and in vivo reduction to practice, high throughput screening, and ultimately coordinating GMP plasmid, virus, and cell manufacturing for translation to the clinic. We are building a cohesive and highly collaborative group. Trainees will have the opportunity to work closely with the Connell O’Reilly GMP Cell Manipulation Core Facility and other collaborators at Dana-Farber and throughout academia and industry in the Boston area and beyond. Through the Scientific and Professional development available in the Eric Smith Lab, we anticipate that lab members will be highly competitive for the many academic or industry positions in the adoptive cellular therapy field upon completion of training. Individuals with expertise in: Immunology; Antibody discovery/development/engineering; Genetic engineering; Single cell RNAseq; Humanized mouse models; Bioinformatics; or other relevant and/or complimentary expertise are encouraged to apply. Applicants should send a cover letter (required), CV, and contact information for three references to the above e-mail address.
In Dr. Smith's role as Director of Translational Research for Immune Effector Cell Therapies, Dr. Smith is happy to be consulted for scientific advice on the following topics:
Labs initiating CAR T cell investigations for the first time
Lab PIs looking to transition pre-clinical work to clinical trials
Investigators thinking about assays on patient samples from clinical trials investigating novel immune effector cell strategies
Any other concept broadly pertaining to translation of adoptive cell therapies from the lab to the clinic or data from clinical trials back to the lab
E-mails from potential collaborators are similarly always welcome.